Vontobel Holding Ltd. Increases Stock Holdings in Stryker Corporation $SYK

Vontobel Holding Ltd. increased its stake in shares of Stryker Corporation (NYSE:SYK) by 2.1% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 100,746 shares of the medical technology company’s stock after purchasing an additional 2,047 shares during the quarter. Vontobel Holding Ltd.’s holdings in Stryker were worth $31,719,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Brighton Jones LLC raised its stake in shares of Stryker by 15.4% in the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after acquiring an additional 609 shares during the period. Schnieders Capital Management LLC. purchased a new position in shares of Stryker during the 2nd quarter worth about $205,000. Marshall Wace LLP boosted its stake in shares of Stryker by 107.9% during the 2nd quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock worth $2,255,000 after purchasing an additional 77,831 shares during the period. Nebula Research & Development LLC bought a new position in Stryker during the 2nd quarter valued at about $219,000. Finally, HUB Investment Partners LLC bought a new position in Stryker during the 2nd quarter valued at about $253,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Trading Down 0.7%

Shares of SYK opened at $338.80 on Friday. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $396.86. The company has a 50-day moving average of $324.61 and a 200 day moving average of $333.57. The firm has a market capitalization of $129.95 billion, a price-to-earnings ratio of 35.11, a PEG ratio of 2.17 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.49 by $0.20. The company had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm’s quarterly revenue was up 9.4% on a year-over-year basis. During the same period in the previous year, the company earned $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, research analysts expect that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a $0.88 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.0%. Stryker’s payout ratio is presently 36.48%.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on SYK. BMO Capital Markets initiated coverage on shares of Stryker in a research note on Wednesday, July 8th. They issued an “outperform” rating and a $369.00 price objective for the company. JPMorgan Chase & Co. cut their target price on Stryker from $400.00 to $350.00 and set an “overweight” rating on the stock in a research note on Friday, July 31st. Citigroup reiterated a “buy” rating on shares of Stryker in a report on Thursday. Leerink Partners decreased their price target on Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a research note on Friday, June 5th. Finally, Sanford C. Bernstein set a $410.00 price objective on Stryker in a report on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, Stryker has an average rating of “Moderate Buy” and an average price target of $386.28.

Insider Buying and Selling

In other Stryker news, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the sale, the vice president directly owned 10,582 shares of the company’s stock, valued at $3,247,298.34. The trade was a 30.04% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the sale, the director owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 4.60% of the stock is currently owned by insiders.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.